<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"><channel><title><![CDATA[CardioKinetix Inc. 보도자료 - 뉴스와이어]]></title><link>https://www.newswire.co.kr/?md=A10&amp;act=article&amp;no=25857></link><description><![CDATA[CardioKinetix Inc. 보도자료 - 뉴스와이어 RSS 서비스]]></description><lastBuildDate>Sat, 16 May 2026 14:29:48 +0900</lastBuildDate><copyright>Copyright (c) 2004~2026 Korea Newswire All rights reserved</copyright><image><url><![CDATA[https://file.newswire.co.kr/data/upfile/company_img/2015/10/3554153577_20151014134144_4860609189.jpg]]></url></image><language>ko-KR</language><item><title><![CDATA[CardioKinetix Announces South Korean Approval for the Parachute System for Heart Failure]]></title><link>https://www.newswire.co.kr/newsRead.php?no=806261</link><description><![CDATA[MENLO PARK, Calif.--(Business Wire/Korea Newswire)--CardioKinetix Inc., a medical device company pioneering a catheter-based treatment for heart failure, today announced that it has received regulatory approval for the Parachute® System in South Korea by the Korean Ministry of Food and Drug Safety (MFDS).  After a heart attack, many patients experience enlargement of their left ventricle causing ...]]></description><pubDate>Wed, 14 Oct 2015 13:45:00 +0900</pubDate></item><item><title><![CDATA[카디오키네틱스, 한국서 심부전용 패러슈트 시스템 승인 획득]]></title><link>https://www.newswire.co.kr/newsRead.php?no=806262</link><description><![CDATA[멘로파크, 캘리포니아--(Business Wire/뉴스와이어)--카테터 기반 심부전 치료에 앞장서고 있는 의료기기회사 카디오키네틱스(CardioKinetix Inc.)가 자사 ‘패러슈트 시스템’(Parachute® System)에 대해 한국 식품의약품안전처(MFDS) 승인을 획득했다고 오늘 발표했다.   심장마비 후 많은 환자에서 왼심실 팽창이 발생하며 이는 숨가쁨과 같은 심부전 증상으로 이어지는 심박출량 감소를 초래한다. 심실 팽창 환자에 대한 치료...]]></description><pubDate>Wed, 14 Oct 2015 13:45:00 +0900</pubDate></item></channel></rss>